

M27

Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

This standard covers antifungal agent selection and preparation, test procedure implementation and interpretation, and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@cls.org

This is a preview. [Click here to purchase the full publication.](#)

Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

Barbara D. Alexander, MD, MHS
Gary W. Procop, MD, MS
Philippe Dufresne, PhD (RMCCM)
Jeff Fuller, PhD, FCCM, D(ABMM)
Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
Kimberly E. Hanson, MD, MHS
Denise Holliday, MT(ASCP)
Nicole M. Holliday, BA
Laura Kovanda, PhD
Shawn R. Lockhart, PhD, D(ABMM)
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute standard M27—*Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts* describes a method for testing the susceptibility to antifungal agents of yeasts that cause invasive fungal infections, including *Candida* spp. and *Cryptococcus neoformans*. Selection and preparation of antifungal agents, implementation and interpretation of test procedures, and the purpose and implementation of QC procedures are discussed. A careful examination of the responsibilities of the manufacturer and the user in QC is also presented.

Clinical and Laboratory Standards Institute (CLSI). *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts*. 4th ed. CLSI standard M27 (ISBN 1-56238-826-6 [Print]; ISBN 1-56238-827-4 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2017.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at: Telephone: +1.610.688.0100; Fax: +1.610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

Copyright ©2017 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts*. 4th ed. CLSI standard M27. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

Previous Editions:

December 1992, October 1995, June 1997, August 2002, April 2008

ISBN 1-56238-826-6 (Print)
ISBN 1-56238-827-4 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 37, Number 13

Committee Membership

Consensus Council

**Carl D. Mottram, RRT, RPFT,
FAARC
Chairholder
Mayo Clinic
USA**

**Dennis J. Ernst, MT(ASCP),
NCPT(NCCT)
Vice-Chairholder
Center for Phlebotomy Education
USA**

J. Rex Astles, PhD, FACB, DABCC
Centers for Disease Control and
Prevention
USA

Lucia M. Berte, MA, MT(ASCP)SBB,
DLM, CQA(ASQ)CMQ/OE
Laboratories Made Better!
USA

Karen W. Dyer, MT(ASCP), DLM
Centers for Medicare & Medicaid
Services
USA

Thomas R. Fritsche, MD, PhD, FCAP,
FIDSA
Marshfield Clinic
USA

Mary Lou Gantzer, PhD, FACB
BioCore Diagnostics
USA

Loralie J. Langman, PhD, DABCC,
FACB, F-ABFT
Mayo Clinic
USA

Ross J. Molinaro, PhD, MLS(ASCP)CM,
DABCC, FACB
Siemens Healthcare Diagnostics, Inc.
USA

Joseph Passarelli
Roche Diagnostics Corporation
USA

Andrew Quintenz
Bio-Rad Laboratories, Inc.
USA

Robert Rej, PhD
New York State Department of Health –
Wadsworth Center
USA

Zivana Tezak, PhD
FDA Center for Devices and
Radiological Health
USA

Subcommittee on Antifungal Susceptibility Tests

**Barbara D. Alexander, MD, MHS
Chairholder
Duke University Medical Center
USA**

**Gary W. Procop, MD, MS
Vice-Chairholder
Cleveland Clinic
USA**

Philippe Dufresne, PhD (RMCCM)
Institut national de santé publique du
Québec
Canada

Jeff Fuller, PhD, FCCM, D(ABMM)
London Health Sciences Centre
Canada

Mahmoud A. Ghannoum, PhD, EMBA,
FIDSA
Case Western Reserve University
USA

Kimberly E. Hanson, MD, MHS
University of Utah and ARUP
Laboratories
USA

Denise Holliday, MT(ASCP)
BD Diagnostic Systems
USA

Nicole M. Holliday, BA
Thermo Fisher Scientific
USA

Luis Ostrosky-Zeichner, MD, FACP,
FIDSA, FSHEA
Memorial Hermann Healthcare System
USA

Audrey N. Schuetz, MD, MPH,
D(ABMM)
Mayo Clinic
USA

Nathan P. Wiederhold, PharmD
University of Texas Health Science
Center at San Antonio
USA

Adrian M. Zelazny, PhD, D(ABMM)
USA

Staff

Clinical and Laboratory Standards
Institute
USA

Marcy L. Hackenbrack, MCM,
M(ASCP)
Project Manager

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

Acknowledgment for the Expert Panel on Microbiology

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the Expert Panel on Microbiology for serving as technical advisors and subject matter experts during the development of this standard.

Expert Panel on Microbiology

**Richard B. Thomson, Jr., PhD,
D(ABMM), FAAM**
Chairholder
Evanston Hospital, NorthShore
University HealthSystem
USA

Mary Jane Ferraro, PhD, MPH
Vice-Chairholder
Massachusetts General Hospital
USA

Lynette Y. Berkeley, PhD, MT(ASCP)
FDA Center for Drug Evaluation and
Research
USA

Carey-Ann Burnham, PhD, D(ABMM)
Washington University School of
Medicine
USA

German Esparza, BSc
Proasecal LTD
Colombia

Mark G. Papich, DVM, MS
College of Veterinary Medicine,
North Carolina State University
USA

Jean B. Patel, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

David H. Pincus, MS, RM/SM(NRCM),
SM(ASCP)
bioMérieux, Inc.
USA

Audrey N. Schuetz, MD, MPH,
D(ABMM)
Mayo Clinic
USA

Ribhi M. Shawar, PhD, D(ABMM)
FDA Center for Devices and
Radiological Health
USA

Barbara L. Zimmer, PhD
Beckman Coulter - West Sacramento
USA

Acknowledgment

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the following volunteers for their important contributions to the development of this standard:

Laura Kovanda, PhD
Astellas Pharma
USA

Shawn R. Lockart, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

Acknowledgment

CLSI, the Consensus Council, and the Subcommittee on Antifungal Susceptibility Tests gratefully acknowledge the following former subcommittee members for their review of this standard during development:

Sharon K. Cullen, BS, PMP, RAC
Beckman Coulter - West Sacramento
USA

David S. Perlin, PhD
New Jersey Medical School-UMDNJ
USA

Nancy L. Wengenack, PhD, D(ABMM)
Mayo Clinic
USA

Shawn R. Lockhart, PhD, D(ABMM)
Centers for Disease Control and
Prevention
USA

Dee Shortridge, PhD
JMI Laboratories
USA